Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biofrontera ( (BFRI) ) has issued an announcement.
On October 23, 2025, Biofrontera Inc. announced the completion of its restructuring and asset purchase agreement with Biofrontera AG, acquiring all U.S. rights to Ameluz® and RhodoLED®, backed by an $11 million investment. This transaction, which includes a reduced earnout structure, is expected to enhance Biofrontera’s financial and operational profile by lowering costs and accelerating the company’s path to profitability. The deal also aligns long-term interests with Biofrontera AG through a 10% equity stake, and positions Biofrontera Inc. to expand Ameluz® growth and explore additional indications.
The most recent analyst rating on (BFRI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s overall score is primarily influenced by its financial performance challenges, including profitability and cash flow issues. Technical analysis shows some positive momentum, but valuation concerns persist due to negative earnings. The earnings call provided a positive outlook with strategic improvements, though financial risks remain significant.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers. The company also conducts clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne.
Average Trading Volume: 174,619
Technical Sentiment Signal: Hold
Current Market Cap: $10.63M
For an in-depth examination of BFRI stock, go to TipRanks’ Overview page.